Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hyposkin

HypoSkin SIGNED

Unique breakthrough ex vivo human skin model to predict efficacy and toxicity of subcutaneous drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HypoSkin project word cloud

Explore the words cloud of the HypoSkin project. It provides you a very rough idea of what is the project "HypoSkin" about.

2017    7    times    first    sharpen    pharmaceuticals    hyposkin    110    1b    vivo    world    cagr    sharp    worldwide    2011    save    88    payed    genoskin    replace    parenteral    34    biopsies    700k    french    feasibility    life    predict    view    animal    off    market    model    founded    provides    patient    sabatier    kit    health    reference    complete    ex    route    decrease    regulatory    home    time    global    innovation    permits    care    turnover    skin    sales    money    framework    sme    causing    ready    drug    national    local    instrument    clinical    issue    cheaper    innovative    paul    spin    trials    fat    reduces    industrialise    biological    limits    containing    university    security    disruptive    pilot    companies    reliably    accurate    administration    living    experiment    quality    medical    tissue    deepen    vitro    standardized    qualify    alternative    faster    human    customers    leads    risks    plans    attrition    company    center    absence    toulouse    device    secure    models    subcutaneous    injection    2024    improves    jobs    confirmed    inadequate    scientific    effect   

Project "HypoSkin" data sheet

The following table provides information about the project.

Coordinator		 GENOSKIN SAS 

Organization address
address: CENTRE PIERRE POTIER, 1 PLACE PIERRE POTIER
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.genoskin.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSKIN SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Subcutaneous injection drug market is highly increasing (CAGR of 7%) and is view as a viable alternative route for parenteral drug administration because it enables at-home injection, improves quality of life and reduces health care costs. However, the absence of accurate biological model to predict the effect of drug injection in the subcutaneous tissue limits their development. That issue leads to 88% of drug attrition causing a loss of more than €1B per developed drug and a sharp decrease of patient security during clinical trials.

HypoSkin is the first and unique in vitro standardized and ready-to-use testing kit containing living ex vivo human skin biopsies with subcutaneous fat, allowing pharmaceuticals to highly reliably predict local human’s response to the injection of a drug or a medical device. This disruptive innovation permits Hyposkin’s customers to save time and money (10 times faster and 5 times cheaper than animal experiment, confirmed in the on-going payed pilot test) as well as secure the development of their products before clinical trials. HypoSkin will become worldwide reference method to replace inadequate animal testing currently used today.

HypoSkin model is developed by Genoskin an innovative French company, founded in 2011 as a spin-off of the French National Center for Scientific Research and the Paul Sabatier University in Toulouse. Genoskin provides other human-skin alternative models to pharmaceuticals companies all over the world leading to sales of €700K in 2017.

The SME Instrument project will allow the company to improve, qualify and industrialise HypoSkin. To accomplish this goal Genoskin will complete a feasibility study to further analyse risks and cost of scale-up, the European regulatory framework and will deepen and sharpen the global subcutaneous injection market. Genoskin plans to lead the European and global alternative method market with an estimated turnover of € 34 M by 2024, and 110 new European and worldwide jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More